Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Comparing Two Acute Care Transition Programs for Older Adults and Their Family Caregivers

29 juillet 2026 mis à jour par: Wake Forest University Health Sciences
This study investigates better ways to help people after they leave the hospital and how to involve their families in this process. The main goal is to see if adding family support to a patient-centered hospital-to-home intervention helps patients stay safely at home, spend fewer days back in the emergency room or going back into the hospital. The study team also wants to see if the family-centered approach helps improve the patient's ability to do everyday activities without feeling overwhelmed. Two approaches are being compared: one focuses just on the patient, and the other includes special strategies to better support families involved too. Family will be involved in assessing what the patient and family needs. The family-focused approach not only emphasizes the experience, health, and safety of the patient but also the experience of the family member caring for the older adult. The study also involves families in education and provides families skills-building experiences that can help with caregiving stress, problem-solving, and communicating with the healthcare team. The approach will help the family member prepare for their loved one's transition home and provide coaching with the goal of reducing the mental, physical and financial burden of providing care at home. To spread the intervention across many states, the study team will be using telephone calls, video calls, and other technologies as families prefer.

Aperçu de l'étude

Description détaillée

For all patients, the transition from hospital to home is a vulnerable period, placing them at great risk for adverse events. In a landmark 2003 report on care transitions, investigators found that 19% of patients experience adverse events soon after discharge (many preventable or ameliorable) and 66% experience adverse drug events. Care transitions also impact those around the recently discharged patient - increasing the burden on family members who provide caregiving support. Without communication and engagement in care transitions, family members experience reduced preparedness for their post-discharge caregiving role, increased caregiver burden, social isolation, and reduced mental/physical well-being.

Patient-centered care transitions can be supported through evidence-based interventions. Recent knowledge generated through PCORI's Transitional Care Evidence to Action Network and other research programs has identified remaining evidence gaps. This Phased Large Award for Comparative Effectiveness Research entitled Comparing Two Acute Care Transition Programs for Older Adults and Their Family Caregivers will create new knowledge related to engaging and supporting family caregivers. After optimization in the feasibility phase, briefly, the Phase 2 comparative effectiveness trial will have the following characteristics:

Setting: 20 Acute Care Hospitals across 5 states selected for rural/urban diversity and patient characteristics Sample: Dyads: Older Adults (N = 1,200) discharged to home and their Family Caregivers (N = 1,200)

Comparators:

Comparator A is an active care transition program that includes effective strategies focused on the patient.

Comparator B includes all Comparator A active strategies, plus focused family caregiver engagement and support.

Randomization:

1:1 Dyad-level RCT stratified by rural/urban home setting and presence of patient cognitive impairment

Patient-Centered Outcomes Include: Patient remaining safely at home (60-day hospital free days), post-discharge adverse events, patient-reported outcomes (e.g.: role functioning). Also, this study extends beyond prior effectiveness research by assessing family-caregiver-reported outcomes (e.g.: caregiver burden).

Type d'étude

Interventionnel

Inscription (Estimé)

2560

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • North Carolina
      • Bermuda Run, North Carolina, États-Unis, 27006
      • High Point, North Carolina, États-Unis, 27262
      • North Wilkesboro, North Carolina, États-Unis, 28659
        • Recrutement
        • Atrium Health Wake Forest Baptist Wilkes Medical Center
        • Contact:
      • Winston-Salem, North Carolina, États-Unis, 27157

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Patient Inclusion Criteria:

  • 65 and older
  • English and Spanish speaking
  • Preadmission location: community dwelling
  • Distance from Hospital: Local and Distant (rural) included
  • Cognitive impairment, dementia allowed
  • Technology Literacy: Flexible from high to low
  • EPIC readmission risk score over 12
  • Discharged home

Patient Exclusion Criteria:

  • Admitted from skilled nursing facility
  • Discharged to skilled nursing facility
  • Left Against Medical Advice (AMA)
  • Planned readmission
  • Died during index admission
  • Caregiver unwilling to participate

Caregiver Inclusion Criteria:

  • Adults 18 and older
  • English and Spanish speaking
  • Providing tangible support to patient
  • Distance from Hospital: Local and Distant (rural) included
  • Only Mild Cognitive Impairment allowed
  • Able to be trained in Video Visit Technology
  • Available to support post-discharge

Caregiver Exclusion Criteria:

• Has a greater than a mild cognitive impairment (< 12 on MCA)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Patient Focused Strategies
An active care transition program that includes effective strategies focused on the patient.
Effective strategies focused on the patient such as patient needs assessment, multi-disciplinary discharge planning, discharge instructions, follow-up education, and follow-up assessments.
Expérimental: Patient and Family Focused Strategies
An active care transition program that includes effective strategies focused on the patient plus focused family caregiver engagement and support.
Effective strategies focused on the patient such as patient needs assessment, multi-disciplinary discharge planning, discharge instructions, follow-up education, and follow-up assessments.
Caregiver strategies such as a family caregiver needs assessment, structured education, and skill building.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Hospital-Free Days
Délai: Day 60
The count of days alive and outside acute care hospitals from discharge to day 60. It will be calculated using EHR and Medicare claims data to objectively capture hospital free days elements (i.e.: mortality days, inpatient days, observation stays, and ED visits).
Day 60

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of Hospital-Free Days
Délai: Day 30, 90, and 180
The count of days alive and outside acute care hospitals from discharge to a specified day. It will be calculated using EHR and Medicare claims data to objectively capture hospital free days elements (i.e.: mortality days, inpatient days, observation stays, and ED visits).
Day 30, 90, and 180
Number of Patient Readmissions
Délai: Day 30, 60, and 90
All-cause, acute care readmissions calculated as both a count and dichotomous using EHR and Medicare claims data.
Day 30, 60, and 90
Zarit Burden Interview Score
Délai: Day 60
Caregiver burden will be measured using the 12-item Zarit Burden Interview. Scores will range from 0 to 48. Higher scores indicate greater burden.
Day 60
Zarit Burden Interview Score
Délai: Day 30, 90, and 180
Caregiver burden will be measured using the 12-item Zarit Burden Interview. Scores will range from 0 to 48. Higher scores indicate greater burden.
Day 30, 90, and 180
PROMIS Ability to Participate in Social Roles and Activities 8-item short form (APS-SF8) Score
Délai: Day 60
Social role function is one's ability to perform usual social roles and activities (e.g.: leisure, family). It will be measured by using the APS-SF8. Each item is scored using a 5-point Likert scale (1=Never, 5=Always). Scores are typically converted to a standardized T-score, with a mean of 50 and a standard deviation of 10.
Day 60
PROMIS Ability to Participate in Social Roles and Activities 8-item short form (APS-SF8) Score
Délai: Day 30, 90 and 180
Social role function is one's ability to perform usual social roles and activities (e.g.: leisure, family). It will be measured by using the APS-SF8. Each item is scored using a 5-point Likert scale (1=Never, 5=Always). Scores are typically converted to a standardized T-score, with a mean of 50 and a standard deviation of 10.
Day 30, 90 and 180
Partners at Care Transitions Measure (PACT-M) - Patient Satisfaction Score
Délai: Day 7
Patient satisfaction will be measured using the 9-item PACT-M-1. Scores will range from 9 to 45. Higher scores indicate better perception of the quality of discharge arrangements.
Day 7
Partners at Care Transitions Measure (PACT-M) - Patient Self-Efficacy Score
Délai: Day 30
Patient self-efficacy will be measured using the 8-item PACT-M-2. Scores will range from 8 to 40. Higher scores indicate a better experience with managing care at home.
Day 30
Patient Activation Measures Score
Délai: Day 60
Patient activation will be measured using the 13-item Patient Activation Measures. Scores will range from 0 to 100. Higher scores indicate greater knowledge, skills, and confidence for managing their health and health care.
Day 60
Preparedness for Caregiving Scale Score
Délai: Day 7
Family caregiver preparedness will be measured using the 8-item Preparedness for Caregiving Scale. Scores will range from 0 to 32. Higher scores indicate better preparedness for the caregiving role.
Day 7
Caregiver Self-Efficacy Scale Score
Délai: Day 30
Family caregiver self-efficacy will be measured using the 8-item Caregiver Self-Efficacy Scale. Scores will range from 8 to 80. Higher scores indicate higher self-efficacy.
Day 30
Caregiver Activation Measures Score
Délai: Day 60
Patient activation will be measured using the 13-item Caregiver Activation Measures. Scores will range from 0 to 100. Higher scores indicate greater knowledge, skills, and confidence for managing their health and health care.
Day 60
Visit Completion Rate
Délai: Day 14 and 30
Number of patients that completed follow-up visit
Day 14 and 30
Time to First Outpatient Follow-up
Délai: Day 14 and 30
Number of days between discharge and first outpatient follow-up visit
Day 14 and 30
Rate of Access to Community Services - Patient
Délai: Day 30 and 60
Number of patients that had screening and intervention assessment for unmet social needs.
Day 30 and 60
Rate of Access to Community Services - Caregiver
Délai: Day 30 and 60
Number of caregivers that had screening and intervention assessment for unmet social needs
Day 30 and 60
Partners at Care Transitions Measures - Adverse Events Score
Délai: Day 7 and 30
Adverse events will be measured using the 7-item Partners at Care Transitions Measures. Scores will range from 7 to 30. Higher scores indicate greater care problems and more adverse events post discharge.
Day 7 and 30
Mortality Rate
Délai: Day 60 and 180
Count of days to date of patient death
Day 60 and 180
Montreal Cognitive Assessment 5-minute Protocol Score
Délai: Day 0, 60, and 180
Cognitive function (attention, orientation, language, memory, and executive function) will be measured using the Montreal Cognitive Assessment 5-min protocol. Scores will range from 0 to 30. Higher scores indicate better cognitive function.
Day 0, 60, and 180

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Thomas Houston, MD, Wake Forest University Health Sciences

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

22 juillet 2026

Achèvement primaire (Estimé)

1 novembre 2031

Achèvement de l'étude (Estimé)

1 novembre 2031

Dates d'inscription aux études

Première soumission

16 juin 2026

Première soumission répondant aux critères de contrôle qualité

16 juin 2026

Première publication (Réel)

22 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

31 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 juillet 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IRB00145199
  • PLACER-2025C1-43844 (Autre subvention/numéro de financement: Patient Centered Outcomes Research Institute)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner